INFLUENZA VIRUS MUTANTS AND USES THEREFOR

WIPO Patent Application WO/2012/177924

A3

Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.

JP2023145596	VACCINATION WITH REPLICON PARTICLES AND OIL ADJUVANT
JP2004503510	Immune sensitization through oral administration of vaccines with edible products
JP2022153576	COMPOSITION AND METHOD COMPRISING IMPROVEMENTS OF CRISPR GUIDE RNAS USING H1 PROMOTER

BILSEL PAMUK (US)
HATTA TASUKO (US)

PCT/US2012/043606

September 06, 2013

June 21, 2012

Click for automatic bibliography generation  

FLUGEN INC (US)
BILSEL PAMUK (US)
HATTA TASUKO (US)

C12N7/01; A61K39/145; C12N15/33

WO1998028478A1

1998-07-02

US20100247572A1	2010-09-30
US20090074812A1	2009-03-19
US20050232950A1	2005-10-20

MATTHEW F. MCCOWN ET AL.: "The Influenza A Virus M2 Cytoplasmic Tail Is Required for Infectious Virus Production and Efficient Genome Packaging.", JOURNAL OF VIROLOGY., vol. 79, no. 6, 2005, pages 3595 - 3605, XP002513971
DATABASE GENBANK [online] 14 November 2006 (2006-11-14), "Influenza A virus segment 7 genes for matrix protein 1 and matrix protein 2, genomic RNA", XP003032551, Database accession no. AJ298948.1
YASUKO HATTAA ET AL.: "An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus.", VACCINE., vol. 29, no. 12, March 2011 (2011-03-01), pages 2308 - 2312, XP028152800

MEARA, Joseph P. (Verex Plaza150 East Gilman Stree, Madison Wisconsin, US)

View/Download PDF      PDF Help

Previous Patent: COCKING AND ADVANCING MECHANISM FOR ANALYTE TESTING DEVICE

Next Patent: AKT INHIBITORS FOR TREATING CANCER EXPRESSING A MAGI3 - AKT3 FUSION GENE